Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 37


Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.

Kim Y, Jeon J, Mejia S, Yao CQ, Ignatchenko V, Nyalwidhe JO, Gramolini AO, Lance RS, Troyer DA, Drake RR, Boutros PC, Semmes OJ, Kislinger T.

Nat Commun. 2016 Jun 28;7:11906. doi: 10.1038/ncomms11906.


Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.


Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.

Fantony JJ, Abern MR, Gopalakrishna A, Owusu R, Jack Tay K, Lance RS, Inman BA.

Urol Oncol. 2015 Sep;33(9):387.e1-6. doi: 10.1016/j.urolonc.2015.04.014. Epub 2015 May 28.


Robotic-Assisted Ureteral Re-implantation: A Case Series.

Wason SE, Lance RS, Given RW, Malcolm JB.

J Laparoendosc Adv Surg Tech A. 2015 Jun;25(6):503-7. doi: 10.1089/lap.2014.0051. Epub 2015 May 15.


A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND.

Clin Cancer Res. 2015 Sep 1;21(17):3862-9. doi: 10.1158/1078-0432.CCR-15-0079. Epub 2015 Apr 29.


Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA.

J Immunother Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.


Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW.

Eur Urol. 2015 Dec;68(6):1083-8. doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25.


Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI.

J Urol. 2014 Oct;192(4):1081-7. doi: 10.1016/j.juro.2014.04.013. Epub 2014 Apr 18.


Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.

Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, Brooks J, Watson MT, Lance RS, Troyer DA, Semmes OJ, Mehta A, Drake RR.

Proteomics Clin Appl. 2013 Oct;7(9-10):677-89. doi: 10.1002/prca.201200134. Epub 2013 Sep 13.


In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, Semmes OJ, Troyer DA, Lance RS, Kislinger T, Drake RR.

Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.


Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS; Canary Prostate Active Surveillance Study Investigators.

Clin Cancer Res. 2013 May 1;19(9):2442-50. doi: 10.1158/1078-0432.CCR-12-3283. Epub 2013 Mar 20.


Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer.

Lambert JW, Ingham M, Gibbs BB, Given RW, Lance RS, Riggs SB.

Urology. 2013 Mar;81(3):587-92. doi: 10.1016/j.urology.2012.10.055. Epub 2013 Jan 24.


NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH.

Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26.


Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.

Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T.

Mol Cell Proteomics. 2012 Dec;11(12):1870-84. doi: 10.1074/mcp.M112.017889. Epub 2012 Sep 17.


Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.

Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA.

J Proteome Res. 2012 Apr 6;11(4):2386-96. doi: 10.1021/pr2011236. Epub 2012 Feb 29.


Molecular pathology of prostate cancer.

Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA.

Cancer Biomark. 2010;9(1-6):441-59. doi: 10.3233/CBM-2011-0181. Review.


Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer.

Lance RS, Drake RR, Troyer DA.

Expert Rev Anticancer Ther. 2011 Sep;11(9):1341-3. doi: 10.1586/era.11.134.


In-depth proteomic analyses of direct expressed prostatic secretions.

Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T.

J Proteome Res. 2010 May 7;9(5):2109-16. doi: 10.1021/pr1001498.


Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.

Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, Lynch DF, Davis JW, Shaves ME, Schellhammer PF.

J Urol. 2010 May;183(5):1822-8. doi: 10.1016/j.juro.2009.12.102. Epub 2010 Mar 29.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk